Base de dados : MEDLINE
Pesquisa : E07.858.740.300 [Categoria DeCS]
Referências encontradas : 1761 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 177 ir para página                         

  1 / 1761 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28551662
[Au] Autor:Matsumoto T; Ichikawa H; Imai J; Hayashi T; Tomita K; Mine T; Kojima S; Watanabe N; Hasebe T
[Ad] Endereço:Department of Radiology, Tokai University Hachioji Hospital, Tokai University School of Medicine, Hachioji, Japan.
[Ti] Título:Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
[So] Source:Anticancer Res;37(6):3183-3187, 2017 06.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: To retrospectively evaluate the feasibility and safety of repeated transarterial chemoembolization (TACE) three or more times using miriplatin-lipiodol (M-LPD) suspension (repeated M-LPD TACE) for hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Sixteen patients who underwent repeated M-LPD TACE were examined. Total dose of miriplatin, lipiodol and porous gelatin sponge particles and adverse events of the first and last M-LPD TACE were evaluated. RESULTS: The mean±standard deviation (SD) of the total number of M-LPD TACE per patient was 3.7±1.1. The mean±SD dose of total miriplatin, lipiodol and porous gelatin sponge particles per patient was 303±103 mg, 21±7.3 ml and 84±57 mg, respectively. There were no significant differences in any adverse events between the first and last M-LPD TACE. CONCLUSION: Repeated M-LPD TACE for HCC is feasible and safe in selected patients.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Carcinoma Hepatocelular/terapia
Quimioembolização Terapêutica/métodos
Óleo Etiodado/administração & dosagem
Neoplasias Hepáticas/terapia
Compostos Organoplatínicos/administração & dosagem
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Antineoplásicos/efeitos adversos
Carcinoma Hepatocelular/patologia
Quimioembolização Terapêutica/efeitos adversos
Esquema de Medicação
Óleo Etiodado/efeitos adversos
Estudos de Viabilidade
Feminino
Esponja de Gelatina Absorvível/administração & dosagem
Seres Humanos
Neoplasias Hepáticas/patologia
Masculino
Meia-Idade
Compostos Organoplatínicos/efeitos adversos
Estudos Retrospectivos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Organoplatinum Compounds); 780F0P8N4I (miriplatin); 8008-53-5 (Ethiodized Oil)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170529
[St] Status:MEDLINE


  2 / 1761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28436697
[Au] Autor:Gaba RC; Kobayashi KR; Bui JT; Lokken RP; Lipnik AJ; Ray CE; Oberholzer J
[Ad] Endereço:1 Department of Radiology, Division of Interventional Radiology, University of Illinois Hospital and Health Sciences System, 1740 W Taylor St, MC 931, Chicago, IL 60612.
[Ti] Título:Liver Track Embolization After Islet Cell Transplant: Comparison of Two Techniques.
[So] Source:AJR Am J Roentgenol;208(5):1134-1140, 2017 May.
[Is] ISSN:1546-3141
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The purpose of this study was to compare the efficacy and safety of microfibrillar collagen paste with those of gelatin sponge for liver track embolization after islet cell transplants. MATERIALS AND METHODS: In a single-institution, retrospective study, 37 patients underwent 66 islet cell transplants from January 2005 through October 2015. Transplants were performed with 6-French transhepatic access, systemic anticoagulation, pretransplant and posttransplant portal venous pressure measurement, and image-guided liver track embolization with gelatin sponge (2005-2011) or microfibrillar collagen paste (2012-2015). The findings on 20 patients (two men, 18 women; mean age, 48 years) who underwent 35 gelatin sponge embolizations were compared with the findings on 13 patients (six men, seven women; mean age, 48 years) who underwent 22 microfibrillar collagen paste embolizations (four patients, nine procedures without embolization excluded). Medical record review was used to compare laboratory test results, portal venous pressures, and 30-day adverse bleeding events (classified according to Society of Interventional Radiology and Bleeding Academic Research Consortium criteria) between groups. RESULTS: The technical success rates were 100% in the microfibrillar collagen paste group and 91% in the gelatin sponge group. Group characteristics were similar, there being no differences in platelet count, partial thromboplastin time, or number of islet cell transplants per patient (p > 0.05). A statistical difference in international normalized ratio (1.0 versus 1.1) was not clinically significant (p = 0.012). Posttransplant portal venous pressure was slightly higher among patients treated with gelatin sponge (13 versus 9 mm Hg, p = 0.002). No bleeding occurred after microfibrillar collagen paste embolization, whereas nine bleeding events followed gelatin sponge embolization (0% versus 26%, p = 0.020). In univariate comparison of bleeding and nonbleeding groups, the use of gelatin sponge was statistically associated with postprocedure hemorrhage. CONCLUSION: Microfibrillar collagen paste is effective and safe for liver track embolization to prevent bleeding after islet cell transplants. It appears to be more efficacious than gelatin sponge.
[Mh] Termos MeSH primário: Colágeno/administração & dosagem
Embolização Terapêutica/métodos
Esponja de Gelatina Absorvível
Hemorragia/prevenção & controle
Hemostasia Cirúrgica/métodos
Hemostáticos/administração & dosagem
Transplante das Ilhotas Pancreáticas
Fígado/irrigação sanguínea
[Mh] Termos MeSH secundário: Meios de Contraste/administração & dosagem
Feminino
Hemostasia Cirúrgica/instrumentação
Seres Humanos
Iohexol/administração & dosagem
Masculino
Meia-Idade
Pomadas
Estudos Retrospectivos
Resultado do Tratamento
Ultrassonografia Doppler
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Contrast Media); 0 (Hemostatics); 0 (Ointments); 4419T9MX03 (Iohexol); 9007-34-5 (Collagen)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170822
[Lr] Data última revisão:
170822
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170425
[St] Status:MEDLINE
[do] DOI:10.2214/AJR.16.17148


  3 / 1761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28413066
[Au] Autor:Wirsching A; Melloul E; Lezhnina K; Buzdin AA; Ogunshola OO; Borger P; Clavien PA; Lesurtel M
[Ad] Endereço:Swiss Hepato-Pancreatico-Biliary and Transplantation Center, Department of Surgery, University Hospital Zurich, Zürich, Switzerland.
[Ti] Título:Temporary portal vein embolization is as efficient as permanent portal vein embolization in mice.
[So] Source:Surgery;162(1):68-81, 2017 Jul.
[Is] ISSN:1532-7361
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Temporary portal vein embolization may be a safe alternative to permanent portal vein embolization. Such a new approach could be applied in living-related liver transplantation to increase graft volume before procurement. The impact of temporary portal vein embolization on occluded liver after recanalization, however, has never been assessed. Using a mouse model of temporary portal vein embolization, we investigated (1) the efficiency of temporary portal vein embolization in inducing nonoccluded liver hypertrophy and (2) the regeneration potential and functional recovery of embolized liver after recanalization. METHODS: Selected portal vein branches were occluded using gelfoam powder (temporary portal vein embolization) or embospheres (permanent portal vein embolization), n = 5/group. Magnetic resonance volumetry and angiography were used to determine volumes of the liver lobe and portal vein branch recanalization. In order to assess the functional and regenerative capacity of occluded liver lobes, nonoccluded lobes were resected 14 days (timespan of complete portal vein recanalization) after temporary portal vein embolization or permanent portal vein embolization. Subsequently, RNA sequencing was performed to compare the signaling pathways of early liver regeneration among the groups. RESULTS: Hypertrophy of nonoccluded lobes 30 days after temporary portal vein embolization and permanent portal vein embolization was similar (103 ± 26% and 129 ± 13%, P = .11). Temporary occluded lobes increased their volumes after nonoccluded lobes resection, reaching similar liver-to-body-weight ratios and similar functional capacity after 7 days compared with partial hepatectomy controls (4 ± 1% vs 4 ± 1%, P = .22). Partial hepatectomy activated similar signaling pathways in temporary occluded and native liver. CONCLUSION: Temporary portal vein embolization induces hypertrophy of contralateral liver lobes similarly to permanent portal vein embolization in mice. This experimental work suggests that temporary portal vein embolization may be considered as a possibility in living liver donation, because regenerative and functional capacities are preserved in the embolized liver after recanalization in mice.
[Mh] Termos MeSH primário: Embolização Terapêutica/métodos
Fígado/patologia
Veia Porta
[Mh] Termos MeSH secundário: Animais
Modelos Animais de Doenças
Esponja de Gelatina Absorvível
Hipertrofia
Fígado/cirurgia
Regeneração Hepática
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Tamanho do Órgão
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170418
[St] Status:MEDLINE


  4 / 1761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28382800
[Au] Autor:Kim YH; Shin HJ; Ju W; Kim SC
[Ad] Endereço:Department of Obstetrics and Gynecology, Ewha Womans University School of Medicine, Seoul, Korea. kimyhmd@ewha.ac.kr.
[Ti] Título:Prevention of lymphocele by using gelatin-thrombin matrix as a tissue sealant after pelvic lymphadenectomy in patients with gynecologic cancers: a prospective randomized controlled study.
[So] Source:J Gynecol Oncol;28(3):e37, 2017 May.
[Is] ISSN:2005-0399
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: This prospective randomized controlled pilot study aimed to find whether gelatin-thrombin matrix used as a tissue sealant (FloSeal) can prevent the occurrence of pelvic lymphocele in patients with gynecologic cancer who has undergone pelvic lymphadenectomy. METHODS: Each patient, who undergo a laparotomic pelvic lymph node dissection on both sides, was randomly assigned for FloSeal application on 1 side of the pelvis. The other side of the pelvis without any product application being the control side. The amount of lymph drainage at each side of the pelvis was measured for 3 days, and computed tomography scans were obtained 7 days and 6 months after surgery for detection of pelvic lymphocele. RESULTS: Among 37 cases, the median amount of lymph drainage was significantly decreased in the hemi-pelvis treated with FloSeal compared to the control hemi-pelvis (p=0.025). The occurrence of lymphocele was considerably reduced in treated hemi-pelvis (8/37, 21.6%) compared with control hemi-pelvis (12/37, 32.4%) after 7 post-operative days (p=0.219), and more decreased in the treated hemi-pelvis (5/37, 13.5%) compared with control hemi-pelvis (9/37, 24.3%) after postoperative 6 months (p=0.344). CONCLUSION: The application of FloSeal as a tissue sealant in lymph nodes resected tissues can reduce the incidence of pelvic lymphocele in gynecologic cancer patients. A large randomized controlled study could confirm these preliminary results.
[Mh] Termos MeSH primário: Esponja de Gelatina Absorvível/uso terapêutico
Neoplasias dos Genitais Femininos/cirurgia
Excisão de Linfonodo/efeitos adversos
Linfocele/prevenção & controle
Complicações Pós-Operatórias/prevenção & controle
[Mh] Termos MeSH secundário: Adulto
Idoso
Drenagem
Feminino
Seres Humanos
Excisão de Linfonodo/métodos
Meia-Idade
Pelve/cirurgia
Projetos Piloto
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (FloSeal Matrix)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170407
[St] Status:MEDLINE
[do] DOI:10.3802/jgo.2017.28.e37


  5 / 1761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28358708
[Au] Autor:Watrowski R; Jäger C; Forster J
[Ad] Endereço:Department of Gynecology and Obstetrics, St. Josefskrankenhaus, Teaching Hospital of the University of Freiburg, Freiburg, Germany Rafal.Watrowski@gmx.at.
[Ti] Título:Improvement of Perioperative Outcomes in Major Gynecological and Gynecologic-Oncological Surgery with Hemostatic Gelatin-Thrombin Matrix.
[So] Source:In Vivo;31(2):251-258, 2017 Mar-Apr.
[Is] ISSN:1791-7549
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: To assess the impact of the use of intraoperative hemostatic gelatin-thrombin matrix (HM) (Floseal®, Baxter Healthcare) on transfusion rates and short-term perioperative outcomes in gynecological surgery. PATIENTS AND METHODS: In this retrospective, single-center study, we evaluated data of 215 patients (83 cases and 132 controls) undergoing extensive gynecological surgery (e.g. oncological procedures) with and without intraoperative HM application. RESULTS: Cases and controls did not differ according to age, preoperative hemoglobin (Hb) concentration, and Hb or C-reactive protein (CRP) levels at discharge. Patients receiving HM had significantly reduced operative (168 vs. 199 min, p=0.02) and hospitalization (9 vs. 14 days, p<0.001) times. The mean postoperative Hb drop (3.33 vs. 4.51 g/dl, p<0.001), and the mean postoperative increase in CRP (94.9 vs. 149.1 mg/l, p<0.001) were significantly less pronounced within the HM group. Despite more prevalent coagulopathy (48 vs. 31%, p=0.02), e.g. due to anticoagulant use (15.7 vs. 3%, p<0.001), patients treated using HM needed less frequent transfusions of packed red blood cells [odds ratio (OR)= 0.13, 95% confidence interval (CI)=0.07-0.24) and fresh frozen plasma (OR=0.51, 95% CI=0.24-1.05). In comparison to controls, the need for surgical revisions (OR 0.1, CI 95% 0.02-0.42) and intensive-care unit admissions (OR 0.15, 95% CI=0.08-0.30) was lower in patients treated with HM. CONCLUSION: To our knowledge, our study is the largest case-control study focusing on Floseal® use in gynecology. The use of HM was associated with significantly better short-term perioperative outcomes. Due to its local action, HM seems to be particularly useful in patients in which anticoagulant medication cannot be paused.
[Mh] Termos MeSH primário: Esponja de Gelatina Absorvível/uso terapêutico
Procedimentos Cirúrgicos em Ginecologia/métodos
Hemostasia Cirúrgica/métodos
Avaliação de Resultados (Cuidados de Saúde)/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Transfusão de Componentes Sanguíneos/estatística & dados numéricos
Perda Sanguínea Cirúrgica/prevenção & controle
Transfusão de Eritrócitos/estatística & dados numéricos
Feminino
Hemostáticos/uso terapêutico
Seres Humanos
Unidades de Terapia Intensiva/estatística & dados numéricos
Tempo de Internação
Meia-Idade
Avaliação de Resultados (Cuidados de Saúde)/estatística & dados numéricos
Admissão do Paciente/estatística & dados numéricos
Período Perioperatório
Plasma
Reoperação/estatística & dados numéricos
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (FloSeal Matrix); 0 (Hemostatics)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170601
[Lr] Data última revisão:
170601
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170331
[St] Status:MEDLINE


  6 / 1761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28258978
[Au] Autor:Özer A; Köstü B
[Ad] Endereço:Department of Obstetrics and Gynecology, Kahramanmaras Sütçü Imam University Hospital, Kahramanmaras, Turkey.
[Ti] Título:Use of Gelatin Sponge Affects Postoperative Morbidity In Cesarean Section Patients.
[So] Source:Med Sci Monit;23:1141-1145, 2017 Mar 04.
[Is] ISSN:1643-3750
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND This study aimed to determine the effects of use of a local hemostatic gelatin sponge (GS) on postoperative morbidity in patients undergoing cesarean section (CS). MATERIAL AND METHODS The records of 318 patients who underwent CS surgery were retrospectively evaluated. Group 1 consisted of 59 patients with gelatin sponge (GS) applied, and Group 2 consisted of 259 patients with no GS applied. The groups were compared for time to the first flatus, nausea and vomiting, requirement for anti-emetic drugs, development of postoperative ileus, and the length of hospitalization. RESULTS The patients in Group 1 and Group 2 were statistically similar in mean age, gravida, parity, and body mass index (BMI) (p=0.352, p=0.275, p=0.458, and p=0.814, respectively). No significant difference was determined in the number of patients with nausea, vomiting, anti-emetic drug use, febrile morbidity, and postoperative ileus (p=0.063, p=0.436, p=328, p=0.632, and p=0.179, respectively). Time to the first flatus and length of hospitalization were significantly longer in Group 2 (p<0.001 and p<0.001, respectively). CONCLUSIONS Delay in recovery of bowel motility may be due to the local hypersensitivity reaction caused by GS and/or dislocation of this local hemostat. Women who receive gelatin sponge treatment during CS should be monitored closely for the recovery of postoperative intestinal motility.
[Mh] Termos MeSH primário: Cesárea/efeitos adversos
Cesárea/métodos
Esponja de Gelatina Absorvível
[Mh] Termos MeSH secundário: Adulto
Antieméticos/administração & dosagem
Feminino
Motilidade Gastrointestinal
Seres Humanos
Morbidade
Complicações Pós-Operatórias/etiologia
Período Pós-Operatório
Gravidez
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiemetics)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170525
[Lr] Data última revisão:
170525
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170305
[St] Status:MEDLINE


  7 / 1761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Ponzoni, Deise
Puricelli, Edela
Texto completo SciELO Brasil
[PMID]:28198971
[Au] Autor:Corsetti A; Bahuschewskyj C; Ponzoni D; Langie R; Santos LA; Camassola M; Nardi NB; Puricelli E
[Ad] Endereço:Universidade Federal do Rio Grande do Sul, Faculdade de Odontologia, Porto Alegre, RS, Brasil.
[Ti] Título:Repair of bone defects using adipose-derived stem cells combined with alpha-tricalcium phosphate and gelatin sponge scaffolds in a rat model.
[So] Source:J Appl Oral Sci;25(1):10-19, 2017 Jan-Feb.
[Is] ISSN:1678-7765
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Objectives: This study aimed to evaluate the potential of adipose-derived stem cells (ASCs) combined with a modified α-tricalcium phosphate (α-TCP) or gelatin sponge (GS) scaffolds for bone healing in a rat model. Material and Methods: Bone defects were surgically created in the femur of adult SHR rats and filled with the scaffolds, empty or combined with ASCs. The results were analyzed by histology and histomorphometry on days seven, 14, 30, and 60. Results: Significantly increased bone repair was observed on days seven and 60 in animals treated with α-TCP/ASCs, and on day 14 in the group treated with GS/ASCs, when compared with the groups treated with the biomaterials alone. Intense fibroplasia was observed in the group treated with GS alone, on days 14 and 30. Conclusions: Our results showed that the use of ASCs combined with α-TCP or GS scaffolds resulted in increased bone repair. The higher efficacy of the α-TCP scaffold suggests osteoconductive property that results in a biological support to the cells, whereas the GS scaffold functions just as a carrier. These results confirm the potential of ASCs in accelerating bone repair in in vivo experimental rat models. These results suggest a new alternative for treating bone defects.
[Mh] Termos MeSH primário: Tecido Adiposo/citologia
Materiais Biocompatíveis/farmacologia
Regeneração Óssea/efeitos dos fármacos
Fosfatos de Cálcio/farmacologia
Esponja de Gelatina Absorvível/farmacologia
Transplante de Células-Tronco/métodos
Tecidos Suporte
[Mh] Termos MeSH secundário: Animais
Materiais Biocompatíveis/uso terapêutico
Fosfatos de Cálcio/uso terapêutico
Adesão Celular/efeitos dos fármacos
Proliferação Celular/efeitos dos fármacos
Células Cultivadas
Fêmur/patologia
Fêmur/cirurgia
Fibroblastos/efeitos dos fármacos
Formazans
Esponja de Gelatina Absorvível/uso terapêutico
Masculino
Modelos Animais
Osteogênese/efeitos dos fármacos
Ratos Endogâmicos SHR
Reprodutibilidade dos Testes
Sais de Tetrazólio
Fatores de Tempo
Resultado do Tratamento
Cicatrização/efeitos dos fármacos
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biocompatible Materials); 0 (Calcium Phosphates); 0 (Formazans); 0 (Tetrazolium Salts); 0 (alpha-tricalcium phosphate); 23305-68-2 (MTT formazan)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170403
[Lr] Data última revisão:
170403
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:170216
[St] Status:MEDLINE


  8 / 1761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28100072
[Au] Autor:Dumberger LD; Overton L; Buckmire RA; Shah RN
[Ad] Endereço:1 University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
[Ti] Título:Trial Vocal Fold Injection Predicts Thyroplasty Outcomes in Nonparalytic Glottic Incompetence.
[So] Source:Ann Otol Rhinol Laryngol;126(4):279-283, 2017 Apr.
[Is] ISSN:1943-572X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Trial vocal fold injection (TVFI) may be used prior to permanent medialization when voice outcome is uncertain. We aimed to determine whether voice outcomes of TVFI are predictive of, or correlate with outcomes after type I Gore-Tex medialization thyroplasty (GMT) in patients with nonparalytic glottic incompetence (GI). METHODS: Thirty-five patients with nonparalytic GI who underwent TVFI followed by GMT were retrospectively reviewed. Change in voice-related quality of life (VRQOL) after TVFI was compared to change in VRQOL 3 to 9 months after GMT. Similar comparisons were made for change in glottal function index (GFI) and change in grade, roughness, breathiness, asthenia, and strain (GRBAS). Sample correlation coefficients were calculated. RESULTS: Change in VRQOL after TVFI showed good correlation with change in VRQOL after GMT, r = 0.55. Change in GFI after TVFI showed strong correlation with change in GFI after GMT, r = 0.74. Change in GRBAS after TVFI showed excellent correlation with change in GRBAS after GMT, r = 0.90. CONCLUSION: The TVFI is a useful tool in nonparalytic GI when outcomes from glottic closure procedures are not clear. Voice outcome measures after TVFI strongly correlate with outcomes from GMT. These data may be used to more confidently counsel patients regarding their predicted outcomes of permanent medialization.
[Mh] Termos MeSH primário: Carboximetilcelulose Sódica/uso terapêutico
Cicatriz/cirurgia
Colágeno/uso terapêutico
Esponja de Gelatina Absorvível/uso terapêutico
Glote
Laringoplastia
Paralisia das Pregas Vocais/cirurgia
Prega Vocal/cirurgia
[Mh] Termos MeSH secundário: Atrofia
Feminino
Seres Humanos
Doenças da Laringe/cirurgia
Masculino
Meia-Idade
Politetrafluoretileno/uso terapêutico
Prognóstico
Qualidade de Vida
Estudos Retrospectivos
Resultado do Tratamento
Voz
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cymetra); 9002-84-0 (Polytetrafluoroethylene); 9007-34-5 (Collagen); K679OBS311 (Carboxymethylcellulose Sodium)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170417
[Lr] Data última revisão:
170417
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170120
[St] Status:MEDLINE
[do] DOI:10.1177/0003489416688479


  9 / 1761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28007079
[Au] Autor:Uflacker A; Sopata CE; Haskal ZJ
[Ad] Endereço:Division of Vascular and Interventional Radiology, University of Virginia, 1215 Lee Street, Charlottesville, VA 22903. Electronic address: andreuflacker@gmail.com.
[Ti] Título:Inferior Epigastric Uterine Artery.
[So] Source:J Vasc Interv Radiol;28(1):23, 2017 Jan.
[Is] ISSN:1535-7732
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Artérias Epigástricas/anormalidades
Esponja de Gelatina Absorvível/administração & dosagem
Hemorragia Pós-Parto/terapia
Embolização da Artéria Uterina/métodos
Artéria Uterina/anormalidades
Malformações Vasculares
[Mh] Termos MeSH secundário: Adulto
Angiografia
Artérias Epigástricas/diagnóstico por imagem
Feminino
Seres Humanos
Hemorragia Pós-Parto/diagnóstico por imagem
Hemorragia Pós-Parto/etiologia
Resultado do Tratamento
Artéria Uterina/diagnóstico por imagem
Malformações Vasculares/diagnóstico por imagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161224
[St] Status:MEDLINE


  10 / 1761 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27826788
[Au] Autor:Haaga J; Rahim S
[Ad] Endereço:Department of Radiology, University Hospitals Case Medical Center, Cleveland, OH, USA.
[Ti] Título:Direct Injection of Blood Products Versus Gelatin Sponge as a Technique for Local Hemostasis.
[So] Source:Cardiovasc Intervent Radiol;40(2):231-235, 2017 Feb.
[Is] ISSN:1432-086X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To provide a method of reducing risk of minimally invasive procedures on patients with abnormal hemostasis and evaluate efficacy of direct fresh frozen plasma injection through a procedure needle tract compared to Gelfoam (gelatin sponge) administration. MATERIALS AND METHODS: Eighty patients with elevated international standardized ratio (INR) undergoing minimally invasive procedures using imaging guidance were selected retrospectively. Forty patients had received Gelfoam as a means of tract embolization during the procedure. The other 40 received local fresh frozen plasma (FFP) through the needle tract. The number of complications and clinically significant bleeding events were recorded. A threshold of 30 cc of blood loss after a procedure was used to identify excess bleeding. RESULTS: No patients experienced clinically significant bleeding after administration of FFP. Five patients experienced postoperative drops in hemoglobin or hematomas after administration of Gelfoam. CONCLUSION: Local injection of blood products can reduce postprocedure bleeding in patients undergoing minimally invasive procedures and provides a safe alternative to the use of synthetic fibrin plugs.
[Mh] Termos MeSH primário: Transfusão de Sangue/métodos
Esponja de Gelatina Absorvível/uso terapêutico
Hemorragia/terapia
Hemostasia
Plasma
[Mh] Termos MeSH secundário: Animais
Feminino
Esponja de Gelatina Absorvível/administração & dosagem
Seres Humanos
Injeções
Masculino
Meia-Idade
Estudos Retrospectivos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161110
[St] Status:MEDLINE
[do] DOI:10.1007/s00270-016-1494-z



página 1 de 177 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde